ReviewVeterinarni medicina2025
Uveodermatological syndrome in dogs: A review of diagnosis, management, and ophthalmic patient needs.
Review in Veterinarni medicina, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveodermatological syndrome is a widely recognised disease that continues to raise significant concern among both veterinarians and pet owners. Its aetiology, although still unclear, is believed to involve an autoimmune origin and genetic predisposition. The most common clinical signs include skin depigmentation, alopecia, poliosis, and, most frequently, granulomatous panuveitis. Affected dogs often develop secondary complications owing to persistent intraocular inflammation, such as cataracts and glaucoma. Although immunosuppressive therapy often yields a favourable response, recurrence is commonly observed. In some cases, uveodermatological syndrome presents a clinical challenge, as patients may experience adverse effects from medications, without which irreversible blindness may ensue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.